Hospira, Inc.  

(Public, NYSE:HSP)   Watch this stock  
Find more results for HSP
0.0000 (0.00%)
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 2.39
Shares 172.93M
Beta     -
Inst. own 79%
Nov 4, 2015
Q3 2015 Hospira Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 12.15% 7.09%
Operating margin 18.47% 10.45%
EBITD margin - 18.27%
Return on average assets 8.65% 4.93%
Return on average equity 16.51% 10.58%
Employees 19,000 -
CDP Score - 58 E


275 N Field Dr
LAKE FOREST, IL 60045-2579
United States - Map
+1-847-9376472 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company's portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. The Company conducts operations across the world and is managed in three segments: the Americas, which include the United States, Canada, and Latin America; Europe, Middle East, and Africa (EMEA), and the Asia Pacific, which includes Asia, Japan, Australia and New Zealand. Its portfolio of products includes Specialty Injectable Pharmaceuticals, which includes generic injectables, injectables and biosimilars, Medication Management and Other Pharmaceuticals. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.